摘要
目的：观察唑来膦酸对体外大鼠成骨细胞增殖及IGF-1表达的影响,进而分析其对成骨质量的影响。方法：采用体外培养的大鼠颅盖骨成骨细胞,用不同浓度的唑来膦酸（10^-4～10^-9 mol/L）处理后,观察其对成骨细胞增殖率以及其分泌IGF-1的影响。结果：唑来膦酸在较高浓度时（≥10^-5 mol/L）明显抑制细胞增殖;唑来膦酸在≤10^-6 mol/L的浓度时并不影响IGF-1的分泌。结论：唑来膦酸在低浓度时不影响成骨质量,考虑到其在体的作用时间更久,所以使用低浓度的唑来膦酸治疗骨质疏松是更明智的选择。
Objective： To investigate whether Zeladronate could affect the proliferation and expression of IGF-1 of in vitro cultured osteoblasts derived from rat,and to analyze its impact on bone formation quality.Methods： Rat calvariae derived osteoblasts were cultured in vitro and then treated with different concentrations of Zoledronate（10^-4-10^-9 mol/L）.The growth of osteoblasts and IGF-1 which were secreted by osteoblasts were studied.Results： Compared with controls treatment with Zoledtonate inhibited osteoblasts appreciation obviously at high concentrations（≥10^-5 mol/L）.Zoledtonate did not affect IGF-1 production at concentrations（≤10^-6 mol/L）.Conclusion： Zeladronate does not affect bone formation quality at low concentrations.Considering its long-term effects in vivo,choosing low-dose concentrations of Zeladronate to treat osteoporosis is a more sensible choice.
出处
《中国医药导报》
CAS
2010年第35期20-21,共2页
China Medical Herald
作者简介
郑振雨（1982-），男，河南安阳人，山西医科大学第二医院2008级骨科硕士研究生；研究方向：骨质疏松及其愈合机制。
【通讯作者】尹芸生（1957-），男，山西朔州人，硕士研究生，骨科主任医师；研究方向：骨质疏松及其愈合机制。
